RR
Therapeutic Areas
Disc Medicine Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Bitopertin | Erythropoietic Protoporphyria (EPP) & X-Linked Protoporphyria (XLP) | Phase 3 |
| DISC-0974 | Anemia of Myelofibrosis (MF) | Phase 2 |
| DISC-3405 | Polycythemia Vera | Phase 2b |
| DISC-0998 | Anemia Associated with Inflammatory Diseases | Preclinical |
Leadership Team at Disc Medicine
JQ
John Quisel, JD, PhD
Chief Executive Officer
JF
Jean Franchi
Chief Financial Officer
JY
Jonathan Yu
Chief Operating Officer
WS
Will Savage, MD, PhD
Chief Medical Officer
PS
Pamela Stephenson, MPH
Chief Commercial Officer
SC
Steve Caffé, MD
Chief Regulatory Officer